Drug Interaction Report
2 potential interactions and/or warnings found for the following 2 drugs:
- leflunomide
- atrasentan
Interactions between your drugs
leflunomide atrasentan
Applies to: leflunomide, atrasentan
GENERALLY AVOID: Coadministration with inhibitors of the hepatic influx transporters organic anion transporting polypeptides (OATP) 1B1 and/or 1B3 may increase the plasma concentrations and adverse effects of atrasentan. In clinical studies, coadministration with the OATP1B1 and 1B3 inhibitor cyclosporine increased the mean systemic exposure (AUC) and peak plasma concentration (Cmax) of atrasentan (single dose, 10 mg) by 380% and 430%, respectively. The risk of adverse effects such as edema, hepatotoxicity and anemia may be increased with this combination.
MANAGEMENT: Concomitant use of atrasentan with OATP1B1 and/or 1B3 inhibitors should generally be avoided.
References (1)
- (2025) "Product Information. Vanrafia (atrasentan)." Novartis Pharmaceuticals
Drug and food interactions
leflunomide food
Applies to: leflunomide
GENERALLY AVOID: The consumption of alcohol during therapy with leflunomide may potentiate the risk of liver injury. Leflunomide has been associated with hepatotoxicity, including elevated liver transaminases, hepatitis, jaundice/cholestasis, hepatic failure, and acute hepatic necrosis,
MANAGEMENT: Patients should be advised to avoid excessive alcohol use during leflunomide treatment.
References (3)
- Cerner Multum, Inc. "UK Summary of Product Characteristics."
- Canadian Pharmacists Association (2006) e-CPS. http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink
- Cerner Multum, Inc. "Australian Product Information."
Therapeutic duplication warnings
No duplication warnings were found for your selected drugs.
Therapeutic duplication warnings are only returned when drugs within the same group exceed the recommended therapeutic duplication maximum.
Drug Interaction Classification
| Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit. | |
| Moderately clinically significant. Usually avoid combinations; use it only under special circumstances. | |
| Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan. | |
| No interaction information available. |
See also:
Humira
Humira is a tumor necrosis factor blocker that is used to treat many inflammatory conditions such ...
Plaquenil
Plaquenil is used to treat or prevent malaria and to treat the symptoms of rheumatoid arthritis ...
Botox
Botox is used to treat chronic migraines, excessive sweating, bladder conditions, eye muscle ...
Enbrel
Enbrel is used to treat rheumatoid arthritis, ankylosing spondylitis, and psoriasis. Learn about ...
Remicade
Remicade is used to treat rheumatoid arthritis, psoriatic arthritis, ulcerative colitis and Crohn's ...
Arava
Arava (leflunomide) is used to treat the symptoms of rheumatoid arthritis and help reduce joint ...
Rituxan
Rituxan infusion is used to treat certain leukemias and lymphomas and some non-cancer conditions ...
Actemra
Actemra is used to treat COVID-19, rheumatoid arthritis, systemic juvenile idiopathic arthritis ...
Orencia
Orencia is a type of biologic that is given by intravenous infusion or subcutaneous injection which ...
Learn more
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
Check Interactions
To view an interaction report containing 4 (or more) medications, please sign in or create an account.
Save Interactions List
Sign in to your account to save this drug interaction list.